Results 41 to 50 of about 687 (60)

Pharmacoeconomic evaluation of pramipexole extended release monotherapy in early Parkinson’s disease

Качественная клиническая практика, 2018
Objective. Health economic expertise of pramipexole extended release monotherapy at early stages of Parkinson’s disease. Methods. An economic model was developed based on clinical studies to derive comparative information on the effectiveness, utility ...
D. Yu. Belousov, E. V. Afanasyeva
doaj  

Pharmacoeconomic analysis of Actemra^® in first-line treatment of rheumatoid arthritis in the modes of combination and monotherapy

Качественная клиническая практика, 2018
Rheumatoid arthritis (RA) is a severe, autoimmune disorder characterized by relatively high prevalence among working-age adult population, significant quality of life and work performance impact, as well as high risk of complete disability in case of ...
S. K. Zyryanov, A. E. Cheberda, D. Yu. Belousov   +2 more
doaj  

Pharmacoeconomical aspects of the treatment of arterial hypertension in patients with type II diabetes mellitus in outpatient department

RUDN Journal of Medicine, 2009
Diabetes mellitus II (DMII) is a chronic disease that has a major social impact. A substantial proportion of the costs of diabetes treatment arises from treating long-term complications, particularly cardiovascular disease (CVD).
J Sh Gushina, E E Loskutova, V K Lepakhin   +2 more
doaj  

The actual practice of clinical nitrition application in the hospitals of Rostov-on-don city and the region

RUDN Journal of Medicine, 2009
The article is devoted to the problem of actual practice of clinical nutrition in the hospitals of Rostov city and Rostov region. The large reserve in application of clinical nutrition - its use in preoperative period.
I N Bychkov
doaj  

Economic expertise of alirocumab in standard lipid lowering therapy insusceptibility

Качественная клиническая практика, 2018
Usage of PCSK9 inhibitors is a new approach of lipid lowering therapy allowing overcomes as well insusceptibility of standard statins’ therapy as their intolerance.
S. K. Zyryanov, I. N. Dyakov
doaj  

Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation

Качественная клиническая практика, 2018
Aim. To perform health-economic evaluation of vemurafenib in comparison to dabrafenib in patients with metastatic or unresectable melanoma with BRAF V600 mutation in Russia from the healthcare system perspective. Materials and methods.
A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin   +3 more
doaj  

Evaluation of direct cost in case of insulin GLA-100rgine-100 switching to insulin GLA-100rgine-300 in diabetes mellitus in real clinical practice

Качественная клиническая практика, 2018
Insulin Glargine-300 (GLA-300) is an innovative basal analogue of insulin that has been released into the market in our country and is prescribed to patients with diabetes mellitus (DM).
D. Yu. Belousov, O. I. Karpov
doaj  

Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs

Folia Medica, 2013
G. Iskrov, Ralitsa Raycheva, R. Stefanov
semanticscholar   +1 more source

Типы и методы проведения научного анализа исходов

Качественная клиническая практика, 2018
Клиническая ценность каждого лекарственного препарата определяется его эффективностью, переносимостью и безопасностью. В связи с появлением на фармацевтическом рынке большого количества препаратов у медицинских работников появилась возможность выбора ...

doaj  

Comparative pharmacoeconomic analysis of ceffaroline fosamil in the treatment of complicated skin and soft tissues infections

Качественная клиническая практика, 2018
The objective was to evaluate the cost-effectiveness and budget impact of ceftaroline fosamil compared with other intravenous antibiotics with anti-MRSA activity in the treatment of complicated skin and soft tissue infections (cSSTI).
S. K. Zyryanov, D. Yu. Belousov, E. V. Afanasyeva   +2 more
doaj